LENZ CFO buys at $22.7561; owns 5,386 common shares

LENZ Therapeutics (LENZ) reported an insider purchase by its Chief Financial Officer, Daniel R. Chevallard.

Rhea-AI Filing Summary

LENZ Therapeutics (LENZ) reported an insider purchase by its Chief Financial Officer, Daniel R. Chevallard. On 11/07/2025, he bought common stock in two open‑market transactions coded “P”: 20 shares at $22.71 and 2,178 shares at $22.7561. Following these trades, he directly owns 5,386 shares.

Insider Trade Summary

Net Buyer: 2,198 shares

Net Buy 2 txns

Insider Chevallard Daniel R.

Role Chief Financial Officer

Bought 2,198 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	20	$22.71	$454.20
Purchase	Common Stock	2,178	$22.7561	$50K

Holdings After Transaction: Common Stock — 5,386 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LENZ (LENZ) disclose?

The CFO, Daniel R. Chevallard, bought LENZ common stock in two open‑market transactions coded P on 11/07/2025.

How many LENZ shares did the CFO purchase and at what prices?

He purchased 20 shares at $22.71 and 2,178 shares at $22.7561.

How many LENZ shares does the CFO own after the transactions?

He directly owns 5,386 shares following the reported transactions.

What is the relationship of the reporting person to LENZ?

He is the Chief Financial Officer of LENZ Therapeutics, Inc.

Was the filing made by one or multiple reporting persons?

It was filed by one reporting person.

What type of form reported this LENZ insider activity?

This activity was reported on an SEC Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 07:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chevallard Daniel R.

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2025		P		20	A	$22.71	3,208	D
Common Stock	11/07/2025		P		2,178	A	$22.7561	5,386	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Daniel R. Chevallard	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.